Mansoor Raza Mirza

Identifying high-risk relapse in early-stage I to II ovarian cancer using the CA125 ELIMination rate constant K (KELIM) score: a Gynecologic Cancer InterGroup individual patient-data meta-analysis.

GOG-3097/ENGOT-ov81/GTG-UK/RAMP 301: a phase 3, randomized trial evaluating avutometinib plus defactinib compared with investigator's choice of treatment in patients with recurrent low grade serous ovarian cancer.

DDRiver EOC 302: A Randomised Phase 2 Study Of Tuvusertib With Niraparib Or Lartesertib In Patients With Epithelial Ovarian Cancer That Has Progressed On Prior PARP Inhibitor Therapy

Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials.

Data from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

Quality-adjusted time without symptoms of disease progression or toxicity of treatment in patients with primary advanced or recurrent endometrial cancer treated with dostarlimab plus carboplatin-paclitaxel versus carboplatin-paclitaxel

Systematic nurse-led consultations based on electronic patient-reported outcomes for women with endometrial or ovarian cancer during chemotherapy-a feasibility study.

Table S3 from Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials

Table S5 from Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials

Data from Molecular Results and Potential Biomarkers Identified from the Phase 3 MILO/ENGOT-ov11 Study of Binimetinib versus Physician Choice of Chemotherapy in Recurrent Low-Grade Serous Ovarian Cancer

Table S7 from Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials

Data from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer

Figure S1 from Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials

Figure 1 from Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials

Figure S3 from Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials

Figure 4 from Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials

Table S7 from Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials

Figure 2 from Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials

Figure S4 from Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials

Data from Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials

SupplementaryGeneTable S1 from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer

Figure S3 from Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials

Table S6 from Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials

Table S8 from Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials

Table S3 from Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials

Table S2 from Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials

Supplementary Material from Beyond HRD Status: Unraveling Genetic Variants Impacting PARP Inhibitor Sensitivity in Advanced Ovarian Cancer

Figure S2 from Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials

Supplementary Appendix 1 from Safety, Efficacy, and Biomarker Analyses of Dostarlimab in Patients with Endometrial Cancer: Interim Results of the Phase I GARNET Study

Table 1 from Potential Synergistic Effect between Niraparib and Statins in Ovarian Cancer Clinical Trials